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Table. Markers of atherosclerosis in relation to prevalent knee OA, stratiﬁed by
gender
Knee OA (Women) OR (95% CI)* Knee OA (Men) OR (95% CI)*
Coronary artery
calciﬁcation
1.11 (0.95–1.30) 1.11 (0.86–1.43)
CD40L 1.32 (1.12–1.56)** 1.05 (0.80–1.37)
VCAM-1 1.31 (1.08–1.59)** 1.08 (0.82–1.42)
VEG-f 1.08 (0.93–1.24) 1.07 (0.90–1.28)
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MARKERS OF ATHEROSCLEROSIS IN RELATION TO PRESENCE AND
PROGRESSION OF KNEE OSTEOARTHRITIS: THE ROTTERDAM STUDY
T.A. Hoeven, M. Kavousi, M.A. Ikram, J.B. van Meurs, P.J. Bindels,
A. Hofman, O.H. Franco, S.M. Bierma-Zeinstra. Erasmus Univ. Med. Ctr.,
Rotterdam, Netherlands
Purpose: Several observational studies have found an association
between subclinical measures of atherosclerosis and osteoarthritis
(OA) of the hands and knees, predominantly among women. Dif-
ferent mechanisms have been suggested to explain the potential
relation between atherosclerosis and OA; systemic low-grade
inﬂammation caused by visceral adipose tissue is particularly men-
tioned and may consequently highlight a route to improve pre-
vention and treatment of atherosclerosis and OA. However, the
reported associations between subclinical measures of athero-
sclerosis and OA were modest in effect size, derived mainly from
cross-sectional studies and generally attenuated after adjustment for
cardiovascular risk factors. Furthermore, previous results were
inconsistent for the different imaging markers of atherosclerosis. In
previous work, we found no relation between peripheral measure-
ments of atherosclerosis (including carotid intima-media-thickness
or carotid plaque) and progression of knee, hand, or hip OA in a
large sample of a prospective cohort study. Hence, it remains unclear
whether atherosclerosis and OA are related or whether they aresimply independent disorders with shared risk factors. Coronary
artery calciﬁcation (CAC) is considered a late stage pathognomonic
feature of coronary atherosclerosis. CD40L, VCAM-1, and VEG-f are
serum biomarkers that reﬂect initial inﬂammatory stages of vascular
wall damage in the ischemic cascade. In the vascular endothelium,
VEG-f is a protein that stimulates angiogenesis, CD-40L and VCAM-1
are molecules that initiate coagulation and immune responses. We
therefore investigated the association between these markers of
early and late atherosclerosis and presence and progression of knee
OA, a possible cardiometabolic phenotype of OA, in a large pop-
ulation-based cohort study.
Methods: The analyses on prevalence of knee OA were performed in
3,465 participants from the prospective population-based Rotterdam
Study (mean age 73.1 years, 61% women). Data on coronary artery
calciﬁcation (CAC) were available for 1,669 participants and plasma
levels of CD40L, VCAM-1, and VEG-f in 975. For the analyses on
progression of knee OA, data on CAC was available for 979 partic-
ipants (17% progressors), and 246 participants (20% progressors) had
plasma levels of CD40L, VCAM-1, and VEG-f. We scored radiographs
of the knee with the Kellgren-Lawrence (K&L) score for osteoarthritis
(knee OA present with a K&L graded score greater or equal to 2) at
baseline and follow-up (average follow-up time 4.5 years (0.5)).
Overall progression of knee OA was deﬁned as the combination of
the incidence and the progression of existing OA at baseline and was
considered present if the K&L score increased 1 grade between
baseline and follow-up visit. After stratiﬁcation by gender, multi-
variate logistic regression models with generalized estimated equa-
tions on knee level were used to calculate odds ratios (95%
conﬁdence intervals) for prevalence and progression of knee OA per
each SD increase in marker levels.
Results: Within the study population, 18% had radiographic knee OA,
11% of the men, 23% of the women. CAC and VEG-f were not associated
with prevalent knee OA. Among women, CD40L (adjusted odds ratio
(aOR) 1.31 (1.12 to 1.56)) and VCAM-1 (aOR 1.31 (1.08 to 1.59)) were
associated with prevalent knee OA (table). No associations with pro-
gression were found in women. In men, too few progressors were
available to assess associations.Conclusions: In this population-based study, coronary artery calciﬁ-
cation and VEG-f were not associated with presence or progression of
knee OA. However, plasma levels of CD40L and VCAM-1 were higher in
women with knee OA and not in men. This might reﬂect an association
between early atherosclerosis and knee OA through low-grade systemic
inﬂammation in women.
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MECHANISMS INVOLVED IN INHIBITION OF INFLAMMATION IN
THP-1 CELLS BY THE HEXADECYLAMIDE DERIVATIVE OF
HYALURONIC ACID.
F. Oliviero y, A. Scanu y, R. Ramonda y, P. Frallonardo y, P. Sfriso y,
J. Dayer z, L. Punzi y. yRheumatology Unit, Univ. of Padova, Padova, Italy;
z Faculty of Med., Geneva, Switzerland
Purpose: Intra-articular injections of hyaluronic acid are widely used in
the treatment of inﬂammatory and degenerative joint diseases. The
immune regulation exerted by hyaluronic acid is modulated by its
interaction with different receptors including CD44 and the toll-like
receptors 2 and 4. A novel hexadecylamide derivative of hyaluronic acid
(HA), HYADD4, has recently been tested in animal models of osteo-
arthritis, showing both anti-inﬂammatory and anabolic effects. The
purpose of this study is to investigate the possiblemechanisms involved
on the effect of unmodiﬁed and hexadecylamide derivative
Fig. 1. Comparison of hs-CRP levels between OA and non-OA
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osteoarthritis process reproduced in vitro.
Methods: The human leukemic monocytic cell line THP-1 was
treated with CPP crystals (0.025 mg/ml) or LPS (500 ng/ml) and
cultured for 24 hours with either simultaneous or 30’ delayed
addition of fresh media containing 0.5 mg/mL unmodiﬁed HA (HN
500-730 kDa, HX >1,500 kDa) or the hexadecylamide derivative of
HA (Hymovis) (HS), all supplied by Fidia Farmaceutici SpA. In some
experiments, cells were primed for 3 h with PMA at 300 ng/ml or
pre-treated for 2 h with CD44 function-blocking monoclonal anti-
body (10 mg/ml) or an isotype control prior to stimulation. The levels
of IL-1ß and IL-8 were determined in the culture supernatants by
ELISA assays. The effect of HA on the phagocytic capacity of THP-1
was evaluated by ordinary/polarized light microscopy. The scavenger
effect of HA on cytokines was determined through the indirect
quantiﬁcation of the binding of these proteins to the chemical
structure of HA. The expression of CD44 on THP-1 cells was assessed
by ﬂuorescence-activated cell sorter (FACS) analysis.
Results: THP-1 cells produce high basal levels of both IL-1ß and IL-8
which further increase after 24 h treatment with CPP crystals. The
addition of 0.5 mg/mL of HA along with the stimulus lead to about
the 60% inhibition of cytokine release using HS with compared to
HN and HX. Any scavenger effect of HS due to the binding of IL-1ß
and IL-8 to its chemical structure was ruled out. HS displayed a
moderate inhibitory effect on crystal phagocytosis. All three deriva-
tives showed a strong inhibitory effect on LPS-induced IL-1ß and IL-
8 production when added simultaneously with the stimulus, but
only HS was able to block inﬂammation once started. This effect was
conﬁrmed in presence of CPP crystals. THP-1 constitutively express
CD44 receptor as evidenced by FACS analysis. Nevertheless, the
incubation with the anti-CD44 antibody did not alter HS effect on
THP-1 inﬂammatory response.
Conclusions: The results of this study show that the hexadecylamide
derivative of HA is able to suppress IL-1ß and IL-8 production after CPP
crystal and LPS stimulation of monocytes. The fact that 1) HS, but not
unmodiﬁed HA, acts also once inﬂammation is triggered, 2) it do not
exhibit scavenger effect and 3) its action is not stimulus-speciﬁc, allows
us to hypothesize that the anti-inﬂammatory activity of HS could be
modulated by its interaction with components/receptors of cell surface
other than CD44, at least in this model.
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CIRCULATING C-REACTIVE PROTEIN IN OSTEOARTHRITIS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
X. Jin y, J. Beguerie z, W. Zhang x, L. Blizzard y, P. Otahal y, G. Jones y,
C. Ding k,y. yMenzies Res. Inst. Tasmania, Hobart, Australia; zDept. of
Dermatology, Austral Univ. Hosp., Buenos Aires, Argentina; xAcademic
Rheumatology, Univ. of Nottingham, Nottingham, United Kingdom;
kDept. of Epidemiology and Preventive Med., Monash Univ., Melbourne,
Australia
Purpose: There is emerging evidence that the development and pro-
gression of osteoarthritis (OA) is associated with inﬂammation. C-
reactive protein (CRP), a systemic marker for inﬂammation, may be
elevated in OA patients but the evidence is conﬂicting. We systemati-
cally reviewed the literature for the relationship between serum CRP
levels measured by a high sensitivity method (hs-CRP) and OA, as well
as the correlation between circulating CRP levels and OA phenotypes.
Methods: MEDLINE, EMBASE and CINAHL databases were systemati-
cally searched from January 1992 to December 2012. Studies were
included when they met the inclusion criteria and data from studies
were extracted. Two independent reviewers assessed study quality
using a modiﬁed Newcastle-Ottawa Quality Assessment Scale (NOQAS).
Meta-analyses were performed to pool available data from included
studies. MEDLINE, EMBASE and CINAHL databases were systematically
searched from January 1992 to December 2012. Studies were included
when they met the inclusion criteria and data from studies were
extracted. Two independent reviewers assessed study quality using a
modiﬁed Newcastle-Ottawa Quality Assessment Scale (NOQAS). Meta-
analyses were performed to pool available data from included studies.
Results: Ten case-control, 15 cross-sectional, 4 longitudinal studies and
3 clinical trials met the criteria and were thus included. Data of 17,090
participants (6,440 OA cases and 10,650 controls) were extracted. The
average methodological quality across included studies was sat-
isfactory. Except for one study showing no difference between OA andcontrols, all other studies revealed that circulating levels of hs-CRPwere
higher in OA patient than in healthy controls (Fig. 1). The pooled mean
difference showed that hs-CRP level was signiﬁcantly higher in OA than
in controls, with an average increase in value of 1.19 mg/l (95% CI 0.64 to
1.73, p< 0.001). The elevation in serum hs-CRP levels was greater in hip
OA than in knee OA, 3.37mg/l (95% CI 0.60 to 6.13) compared to 1.15mg/
l (95% CI 0.18 to 2.12). The links between serum hs-CRP levels and knee
radiographic OA were investigated in four studies. The pooled correla-
tion coefﬁcient showed that the link between serum hs-CRP levels and
knee radiographic OAwas weak and it was not statistically signiﬁcant (r
¼ 0.11, 95% CI 0.03 to 0.26, p ¼ 0.13). The correlation coefﬁcients
between hs-CRP levels and pain in OA patients were available in six
studies. The pooled result of the meta-analysis showed that there was a
weak but statistically signiﬁcant correlation between hs-CRP levels and
pain scale score (r ¼ 0.14, 95% CI 0.08 to 0.20, p < 0.001). There was no
signiﬁcant heterogeneity observed across the studies (Chi2 ¼ 4.12, p ¼
0.39; I2 ¼ 3%). Two studies reported the correlation coefﬁcient of hs-
CRP with physical function. The results from both studies were con-
sistent with each other, indicating a correlation between increased hs-
CRP levels and worsening physical function. The pooled correlation
coefﬁcient was statistically signiﬁcant (r ¼ 0.26, 95% CI 0.13 to 0.39, p <
0.001)
Conclusions: OA is chronic joint disorder with low grade systemic
inﬂammation as reﬂected by increased serum hs-CRP levels. Low-grade
systemic inﬂammation may play a greater role in symptoms rather than
radiographic changes in OA.511
OLIGOMYCIN, AN INHIBITOR OF COMPLEX V OF THE
MITOCHONDRIAL RESPIRATORY CHAIN, INDUCES AN
INFLAMMATORY AND OXIDATIVE RESPONSE IN RAT KNEE JOINT.
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A. Centeno-Cortes z, R.R. Riveiro-Naveira y, M.N. Valcarcel-Ares y,
F.J. Blanco x, M.J. Lopez-Armada y. yAging and Inﬂammation Res. Lab,
INIBIC - CHU A Coru~na, A CORU~NA, Spain; z Experimental Surgery Unit,
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Purpose: Inﬂammation is now recognized as a pivotal player in articular
damage pathways in OA. A decline of mitochondrial function has been
described in OA chondrocytes and RA synoviocytes. Recent ex vivo ﬁnd-
ings support a connection between mitochondrial dysfunction and acti-
vation of inﬂammatoryanddestructive pathways in these cells. The aimof
this studywas to investigate in vivowhether the intraarticular injection of
oligomycin (OLI), an inhibitor of mitochondrial function, induces a
destructive, oxidative and inﬂammatory response in rat knee joints.
Methods: 45 female wistar rats (180–220 g) were randomized into
three study groups: Healthy (no intraarticular injection); Lip-
opolysaccharide (LPS)-treated, positive control (left joint injected with
10 mg LPS); and OLI-treated (left joint injected with 20 mg OLI). Right
joints were treated with the respective vehicles. Intraarticular injec-
tions were carried out on day 0, 2 and 5, and rats were euthanized on
day 6. Hind paws were collected and joint tissues were obtained.
Measurement of joint diameters on stimulis- and control-injected paws
was performed on days 0 and 6. Histopathologic lesions were evaluated
by Hematoxilyn-Eosin (H&E) and Masson Trichromic Staining in syno-
vial tissue and by Safranin O staining in cartilage. ROS production was
